TREAT-NMD is taking bold steps to ensure it remains at the forefront of innovation in rare disease care. As a global leader in advancing treatments for neuromuscular disease through education, data, and collaborative networks, TREAT-NMD is now investing in developing future-proofed technology solutions to better serve the patient community.
A cornerstone of this effort is our leadership in the European-funded PaLaDIn project. At the heart of PaLaDIn is Interactium—a next-generation platform designed to securely combine diverse data sources to provide a holistic understanding of rare diseases and elevate the patient voice in clinical and policy decision-making.
To support this ambitious journey, TREAT-NMD has established a revitalized Information Technology Advisory Committee (ITAC), bringing together exceptional expertise to challenge, guide, and future-proof our digital strategy.
The new ITAC will be chaired by Barbara Harpham (former CEO of Heart Research UK and Chair of the Medical Technology Group), alongside Alan Timothy (TREAT-NMD CTO), and Graham Kay (Paladin WP5 Project Lead and Secretariat). The group is further strengthened by David Raper, a seasoned technology operations leader advising on IT infrastructure and cloud strategy, and Lesley Chapman, a retail brand and customer experience expert focusing on user engagement and retention.
The Committee held its inaugural meeting this week and received an overview of the Interactium vision and the Paladin workstreams. Additional members will be appointed to ensure well-rounded, external scrutiny of our technology development.
This is a significant milestone that reinforces TREAT-NMD’s commitment to leveraging technology for the benefit of patients worldwide.
To find out more about the committee and the PaLaDin project please contact: info@treat-nmd.com
